Good morning, ladies and gentlemen, and welcome to the Sandoz call today. I will now pass on to Craig Marks, Head of Investor Relations, for his opening remarks. Thank you. Welcome to the Sandoz Q1 ...

We have seen a steady increase in the use of blood based biomarkers, the conversion rates from diagnosis ... ejection fraction indication for Tirzepatide. We believe the positive Phase 3 data ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

A recent analysis of the SURPASS-3 trial unravels the impact of treatment with the drug tirzepatide on muscle volume and fat ...

The future for GLP-1RA compounders, steps pharma can take in light of rising trial costs, funding ultra-rare therapies, and ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

A recent analysis of the SURPASS-3 trial unravels the impact of treatment with the drug tirzepatide on muscle volume and fat infiltration in individuals with type 2 diabetes. Published in The ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying patients. Semaglutide, the first weekly GLP-1 RA for weight management ...

Novo Nordisk's oral GLP-1 drug Rybelsus, which also has the same active ingredient semaglutide ... Lilly's injectable tirzepatide is sold under the brand names Mounjaro for diabetes and Zepbound ...